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Abstract
Stem cell factor (mouse: Kitl, human: KITLG) and insulin-like growth factor-1 (IGF1), acting via KIT and IGF1 receptor
(IGF1R), respectively, are critical for the development and integrity of several tissues. Autocrine/paracrine KITLG-KIT
and IGF1-IGF1R signaling are also activated in several cancers including gastrointestinal stromal tumors (GIST), the
most common sarcoma. In murine gastric muscles, IGF1 promotes Kitl-dependent development of interstitial cells of
Cajal (ICC), the non-neoplastic counterpart of GIST, suggesting cooperation between these pathways. Here, we
report a novel mechanism linking IGF1-IGF1R and KITLG-KIT signaling in both normal and neoplastic cells. In
murine gastric muscles, the microenvironment for ICC and GIST, human hepatic stellate cells (LX-2), a model for
cancer niches, and GIST cells, IGF1 stimulated Kitl/KITLG protein and mRNA expression and promoter activity by
activating several signaling pathways including AKT-mediated glycogen synthase kinase-3β inhibition (GSK3i).
GSK3i alone also stimulated Kitl/KITLG expression without activating mitogenic pathways. Both IGF1 and GSK3i
induced chromatin-level changes favoring transcriptional activation at the Kitl promoter including increased histone
H3/H4 acetylation and H3 lysine (K) 4 methylation, reduced H3K9 and H3K27 methylation and reduced occupancy
by the H3K27 methyltransferase EZH2. By pharmacological or RNA interference-mediated inhibition of chromatin
modifiers we demonstrated that these changes have the predicted impact on KITLG expression. KITLG knock-down
and immunoneutralization inhibited the proliferation of GIST cells expressing wild-type KIT, signifying oncogenic
autocrine/paracrine KITLG-KIT signaling. We conclude that membrane-to-nucleus signaling involving GSK3i
establishes a previously unrecognized link between the IGF1-IGF1R and KITLG-KIT pathways, which is active in
both physiologic and oncogenic contexts and can be exploited for therapeutic purposes.
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Introduction
Stem cell factor (mouse: Kitl; human: KITLG) is the natural
ligand of the type 3 receptor tyrosine kinase (RTK) KIT. Kitl/
KITLG is widely expressed in stromal tissues and is critical for
the differentiation, proliferation, migration, survival and
functional activation of germinal, erythroid and mast cells and
melanocytes [1], as well as interstitial cells of Cajal (ICC),
gastrointestinal mesenchymal cells that generate electrical
rhythmicity and mediate nerve-smooth muscle interactions [2].
Kitl/KITLG is a non-covalent homodimer and exists as a
membrane-bound or locally secreted peptide [3]. A 164-amino-
acid secreted isoform results from proteolytic cleavage of the
248-amino-acid, transmembrane peptide (“soluble” isoform;
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Kitl248/KITLG248) at a site encoded within exon 6. A 220-amino-
acid isoform, which only generates secreted peptide at a slow
rate, is produced from an alternatively spliced transcript lacking
exon 6 (“membrane-bound” isoform; Kitl220/KITLG220) [3].
Autocrine/paracrine activation of KIT signaling by KITLG plays
a role in several tumors and hematologic malignancies [1]. In
other cancers including the majority (75-80%) of
gastrointestinal stromal tumors (GIST), which originate from
cells of the ICC lineage [4,5], KIT signaling is constitutively
active due to oncogenic mutations [6]. GIST lacking mutated
KIT may harbor activating mutations in PDGF receptor α
(PDGFRA) [7] or have neither KIT nor PDGFRA mutations
(“wild-type (WT)” GIST) [6]. KIT/PDGFRA inhibitors such as
imatinib mesylate are the mainstay of medical treatment for
advanced GIST but they are not curative due in part to
secondary mutations interfering with drug action [6] or lack of
dependence of cancer-initiating cells on KIT/PDGFRA signaling
[8]. Since imatinib preferentially targets mutant receptors [6],
reduced drug responsiveness [9,10] and aggressive GIST
behavior [11] may also reflect activation of WT KIT expressed
in the majority of GIST by KITLG originating from the
circulation, the tumor cells, or their niche [9,11-13]. However,
direct evidence of KITLG-driven GIST cell proliferation is
lacking.
Similarly to KIT, PDGFRA and their ligands, insulin-like
growth factor (IGF)-1 receptor (IGF1R), a type 2 RTK, and its
ligands IGF1 and IGF2 play critical roles in normal growth and
development, as well as in cellular stress, aging and cancer by
stimulating protein synthesis and the cell cycle [14,15]. IGF1R
is expressed and activated in some GIST [16] and is
overexpressed in WT GIST [16,17]. Via an autocrine loop,
IGF1 stimulates the growth and survival of gastrointestinal
smooth muscle cells [18-20], and, thereby, promotes the
differentiation of ICC [21] by increasing Kitl availability in their
microenvironment [22]. IGF1 also activates gene transcription
e.g. via p44/p42 mitogen-activated protein kinase (ERK1/2
MAPK) signaling [15] or by promoting the nuclear translocation
and binding to the chromatin of IGF1R [23]. Together, these
observations suggest that there may be cooperation between
the IGF1-IGF1R and KITLG–KIT signaling pathways both in
normal tissues and certain cancers including GIST; these
interactions may be mediated by epigenetic control of gene
transcription; and increased Kitl/KITLG expression may result
in autocrine/paracrine stimulation of proliferation in cells
expressing WT KIT. Here, we tested these hypotheses by
investigating the effects of IGF1 on endogenous Kitl/KITLG
expression and the underlying epigenetic mechanisms and
signaling pathways in IGF1R-expressing cells and tissues
including gastric smooth muscles [18-20,22], the natural
microenvironment for ICC and GIST; in human GIST cells
[10,16], and in LX-2 human hepatic stellate cells [24], a model
for cancer niches [25]. Our findings indicate that IGF1
stimulates KITLG transcription by inducing coordinated
chromatin modifications in part via glycogen synthase kinase
(GSK)-3β inhibition. We also provide evidence supporting
KITLG-mediated autocrine/paracrine stimulation of cell
proliferation in GIST cells expressing WT KIT.
Materials and Methods
Ethics statements
Mice were maintained and the experiments were performed
in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. The protocol was
approved by the Institutional Animal Care and Use Committee
of the Mayo Clinic (A64812). De-identified human gastric
tissues used for the preparation of primary cell cultures were
obtained as surgical waste tissue from patients undergoing
bariatric surgery with the approval of the Mayo Clinic
Institutional Review Board (07-003371). The Mayo Clinic
Institutional Review Board waived the need for written informed
consent from the participants.
Tissue preparation
BALB/c mice aged 14-16 days were obtained from breeder
pairs purchased from Harlan Laboratories (Madison, WI).
LONG R3-recombinant human IGF1 (LR3-rhIGF1; Research
Peptides, Orlando, FL) was administered by a single i.p.
injection. Mice were anesthetized with isoflurane (AErrane;
Baxter Healthcare, Deerfield, IL) inhalation and killed by
decapitation. Intact gastric corpus and antrum tunica
muscularis tissues were dissected as described [22] and used
either as organotypic cultures [22] or primary cell cultures [26].
Primary cell cultures were prepared from human tunica
muscularis as described for murine tissues [26].
Tissue culturing and drug treatment
Gastric tunica muscularis organotypic cultures were
maintained for up to 24 h. Pharmacological agents were
applied as indicated in the Results and Figures. In some
experiments tissues were preincubated for 3 h with specific,
cell-permeable inhibitors or dimethyl sulfoxide (DMSO) vehicle
before exposure to rhIGF1 for 18 h in the continuing presence
of the inhibitors. Pharmacological agents included rhIGF1, the
ATP-competitive GSK3α/β inhibitors SB415286 and SB216763
[27], the non-ATP-competitive GSK3α/β inhibitor TDZD-8 [28],
adenosine dialdehyde (Adox) [29], an inhibitor of S-
adenosylhomocysteine hydrolase and indirect inhibitor of S-
adenosyl-methionine-dependent methylation reactions
including trimethylation of lysine 27 of histone 3 (H3K27me3)
by the polycomb repressive complex 2 (PRC2) member
enhancer of zeste homolog 2 (EZH2) (Sigma-Aldrich, St. Louis,
MO); Tyrphostin AG1024, a specific inhibitor of IGF1 and
insulin RTK activity [30]; AKT Inhibitor X (10-(4'-(N-
diethylamino)butyl)-2-chlorophenoxazine, HCl), an inhibitor of
AKT phosphorylation, in-vitro kinase activity and IGF1-induced
nuclear translocation [31]; rapamycin, inhibitor of mechanistic
target of rapamycin (MTOR) complex 1 and ribosomal p70 S6
kinase (p70S6K) phosphorylation [20]; and PD98059, inhibitor
of MEK1/2 ERK MAPK kinases [32] (EMD Chemicals, Inc.,
Gibbstown, NJ).
Cell cultures and antibody/drug treatment
Primary cell cultures prepared from human or murine gastric
smooth musculature were maintained as described previously
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[26]. Stromal cells derived from the fetal hematopoietic
microenvironment of Kitl-deficient Sl/Sl4 mice, Sl/Sl4 stromal
cells genetically modified to express full-length murine Kitl
(Sl/Sl4-Kitl248) (generously donated by Dr. David Williams,
Indiana University School of Medicine, Indianapolis, IN) [3],
human LX-2 spontaneously immortalized hepatic stellate cells
(kindly provided by Dr. Scott Freeman, Mount Sinai School of
Medicine, New York, NY) [33], and human GIST-T1 cells
derived from metastatic pleural tumor from a gastric GIST
containing a heterozygous deletion of 57 bases in exon 11
juxtamembrane domain of KIT (contributed by Dr. Takahiro
Taguchi) [34] were cultured in high-glucose Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, Life Technologies,
Carlsbad, CA) containing 10% fetal bovine serum (FBS) and
1% antibiotic-antimycotic (Gibco) at 37 °C in the presence of
5% CO2. GIST-T1-5R cells derived from GIST-T1 cells by
prolonged in vitro exposure to imatinib and carrying a
secondary, imatinib-resistant T670I mutation in exon 14
(contributed by Dr. Anu Gupta and Dr. Brian P. Rubin) were
propagated in the presence of 1 µM imatinib mesylate (LC
Laboratories, Woburn, MA). Imatinib was removed from the
culture media 4 days prior to the experiments. GIST882 human
cells from a primary GIST containing a homozygous KIT exon
13 missense mutation leading to K642E substitution in the first
part of the split tyrosine kinase domain (contributed by Dr.
Jonathan Fletcher) [35] were also cultured in high-glucose
DMEM containing 10% FBS and 1% antibiotic-antimycotic but
were maintained in a milieu of 4% O2, 5% CO2 and 91% N2.
GIST48B KITlow/– human cells derived from GIST48 cells
containing KIT exon 11 (homozygous V560D: imatinib-
sensitive) and exon 17 phosphotransferase domain
(heterozygous D820A: imatinib-resistant) mutations by
prolonged heat shock protein 90 inhibition (contributed by Dr.
Jonathan Fletcher) [36] were maintained with Iscove’s DMEM
(high glucose) containing 15% FBS, 1% L-glutamine and 1%
antibiotic-antimycotic (Gibco) at 37 °C in the presence of 5%
CO2. LX-2, GIST-T1 and GIST882 cells have previously been
demonstrated to express IGF1R [16,24]; results showing
IGF1R α and β chain expression in GIST48B cells and IGF1
secretion by LX-2, GIST-T1, GIST882 and GIST48B cells are
shown in Figure S1F-G. The role of endogenous KITLG in the
proliferation of GIST-T1, GIST-T1-5R, GIST882, GIST48B and
LX-2 cells was tested by culturing in the above media in the
presence of purified, azide-free goat polyclonal anti-human
KITLG antibody (AB-255-NA, R&D Systems, Minneapolis, MN;
applied for 4 days at concentrations indicated in the Results),
which has been shown to neutralize KITLG-induced
proliferation in the TF1 human erythroleukemic cell line [37].
The specificity of KITLG immunoneutralization was verified by
preabsorbing the anti-KITLG antibody with rhKITLG (R&D
Systems) applied at 10:1 molar ratio overnight at 4 °C. Cell
proliferation was assessed by the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, WI)
according to the manufacturer’s protocol. To examine the
effects of directly modifying the epigenetic status of chromatin
on KITLG expression, LX-2 and GIST-T1 cells were treated
after 24-h serum starvation with the following specific, cell-
permeable drugs or DMSO vehicle for 24-72 h at the
concentrations indicated in the text: Adox, BIX-01294, a non-S-
adenosyl-methionine analog-based inhibitor of the histone-
lysine methyltransferases (HKMT) G9A (EHMT2) and GLP
(EHMT1) and the H3K9me1/2 (histone H3 lysine 9 mono/
dimethylation) modification they catalyze [38,39]; chaetocin, an
S-adenosyl-methionine-competitive inhibitor of the SUV39
family of H3K9 HKMTs including G9A, GLP and SUV39H1
[39,40]; garcinol, an inhibitor of histone acetyltransferases
(HAT) p300 (EP300) and PCAF (KAT2B) (Sigma-Aldrich) [41];
and suberoylanilide hydroxamic acid (SAHA; vorinostat), a
class I-II histone deacetylase (HDAC) inhibitor (Santa Cruz
Biotechnology, Dallas, TX) [42].
RNA interference (RNAi)
RNAi against KITLG and heterochromatin protein 1 (HP1)
homolog α (CBX5) was performed using Dharmacon ON-
TARGETplus® SMARTpool® small interfering RNA (siRNA) or
corresponding scrambled sequences (25 nM) and
DharmaFECT 4 Transfection Reagent (Thermo, Fisher
Scientific, Waltham, MA) according to the manufacturer’s
protocol. HP1β (CBX1) and HP1γ (CBX3) were targeted with
short hairpin RNAs (shRNAs) containing 19-mer antisense
sequences (HP1β: GAAAGGGAGATGGGTAGCATC; HP1γ:
GCAAATCAAAGAAGAAAAG). The sense-loop-antisense-
terminator shRNA template inserts were cloned in under the
RNA polymerase III H1 promoter in a bicistronic plasmid
assembled to express green fluorescent protein from a CMV
promoter. Plasmids were transformed into DH5a competent
cells (Invitrogen, Carlsbad, CA), expanded and purified using a
Plasmid Maxi Kit (QIAGEN, Germantown, MD). Plasmids (30
µg) were electroporated 3 times into LX-2 cells. Transfection
efficacy was estimated after 24 h by fluorescence microscopy;
cells were harvested after 72 h. Off-target effects were
controlled for by transfecting cells with empty vectors.
Reverse transcription-polymerase chain reaction (RT-PCR).
Kitl/KITLG transcription was monitored by real-time or
traditional RT-PCR (see details including controls in ref [43].)
using specific, intron-spanning primers published previously
[22] or designed for this study (human KITLG exons 1-2:
forward: TGCGCTCGGGCTACCCAATG; reverse:
GCAGATCCCTTCAGTTTTGACGAGAG). Transcriptional
quantification was obtained by the ΔΔCT method on a Bio-Rad
Laboratories (Hercules, CA) CFX96 real-time PCR detector.
KITLG transcriptional activity
A human KITLG promoter-pGL3b luciferase construct was
generated in a two-step process. First, a 1452-bp product of
the 5' promoter region (-2120 bp to -669 bp) of KITLG was
obtained by PCR amplification of human genomic DNA using
specific primers. The 5' primer contained a KpnI restriction site
at the 5' end for incorporation into the vector. The BglII site
contained within the promoter region (-842 bp to -837 bp) was
utilized as the 3' restriction site and the 1280-bp KpnI-BglII
digestion product was ligated into the KpnI-BglII sites of the
pGL3 basic vector (Promega). The 5' KITLG promoter
sequence was confirmed and, subsequently, the vector was
reopened at the BglII site. A 1280-bp product of the 3' KITLG
promoter region (-873 bp to +407 bp) was amplified by PCR,
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utilizing human genomic DNA and specific primers with the 3'
primer containing a BglII site at the 5' end for incorporation into
the vector. Again, the BglII site contained within the promoter
region was utilized this time as the 5' restriction site and the
1245 bp BglII-BglII digestion product was ligated into the BglII
site of the 5' KITLG promoter (-2120 bp to -837 bp)-pGL3b
construct. Orientation and the entire promoter sequence was
confirmed by sequencing to obtain the full length KITLG
promoter (-2120 bp to +407 bp)-pGL3b luciferase construct.
Transfection of LX-2 and GIST-T1 cells, as well as primary cell
cultures prepared from murine gastric smooth muscles was
performed as described above. Cells were harvested, lysed
and assayed for luciferase activity 48 h after transfection using
the Promega Luciferase Assay System.
Western immunoblotting
Tissue and cell lysates were prepared and subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
immunoblotting as described previously [44] (see antibodies in
Table S1). Bound antibodies were visualized using an Odyssey
Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) and
Bio-Rad Quantity One 4.5.1 software. Protein and
phosphoprotein bands of interest were expressed in
densitometric units normalized to the loading control
(glyceraldehyde-3-phosphate dehydrogenase; Gapdh/GAPDH
or β-actin; Actb) and the corresponding total protein,
respectively, detected simultaneously in the same sample.
Chromatin immunoprecipitation (ChIP)
DNA–protein complexes from juvenile murine gastric smooth
muscle were cross-linked using fresh 1% formaldehyde
(Thermo, Fisher) for 10 minutes, followed by glycine
quenching. DNA-protein complexes were sheared on cold
water using a Bioruptor sonicator (Diagenode, Denville, NJ) at
settings optimized for obtaining DNA fragments ranging from
~150 to 600 bp. Histone and chromatin-binding proteins were
purified and immunoprecipitated overnight at 4 °C along with
bound DNA fragments using reagents and magnetic beads
from a EZ-Magna ChIP™ G Chromatin Immunoprecipitation Kit
(Millipore, Billerica, MA) and ChIP-grade antibodies against
EZH2, H3K27me3, H3K4me2 (dimethylated lysine 4 of histone
3), H3K9me2, H3K9me3, H3K9ac (acetylated lysine 9 of
histone 3) and H4ac (acetylated histone 4) (Table S2). The
ability of these antibodies to enrich target DNA was verified by
PCR and antibodies against RNA polymerase II (positive
control), Gapdh (negative control) and “non-immune” mouse
IgG (negative control). Bound DNA fragments were isolated by
proteinase K digestion for 2 hours at 62 °C, and magnetic
beads were dissociated by incubation at 95 °C for 10 minutes.
Immunoprecipitated DNA fragments were analyzed by
quantitative real-time PCR using primers designed to target the
mouse Kitl promoter (-300 bp to -214 bp): forward:
GCTGGTGAGCTTGCTGCGGA; reverse:
TGAGGCACCGGGAGTCTCGG. PCR results were quantified
by the ΔΔCT method using input DNA as reference and the
vehicle (DMSO)-treated samples as control.
Statistical analyses
Each data point (n) represents one freshly isolated or
cultured stomach or a biological replicate experiment in
cultured cells. Data are expressed as mean ± standard error of
the mean (SEM) or median and interquartile range. Student’s t
test or Mann-Whitney rank sum test were used for comparing
two data sets. Three groups or more were compared by one-
way analysis of variance (ANOVA) or ANOVA on ranks
followed by multiple comparisons. A probability value of P<0.05
was used as a cut-off for statistical significance in all statistical
procedures. IC50 values were obtained by nonlinear curve fitting
applied to dose-response data using the equation library in
SigmaPlot 10.0 (Systat Software, Chicago, IL).
Results
Kitl/KITLG protein is expressed in IGF target cells and
tissues
We investigated Kitl/KITLG protein expression in IGF1R-
expressing gastrointestinal smooth muscles [18,20,22], LX-2
hepatic stellate cells [24] and GIST cell lines (see ref [16]. and
Figure S1F). In murine gastric muscles, Kitl protein could be
readily detected by Western immunoblotting as a ~31-kDa
band (Figure S1A) corresponding to uncleaved, cell-associated
Kitl220 and secreted Kitl produced from the Kitl248 isoform [3].
Occasionally, we also detected a 43-kDa band likely
representing residual, uncleaved Kitl248 and a 21-kDa band,
which corresponds to secreted Kitl produced from Kitl220 [3].
However, the low abundance of these minor peptides did not
allow quantification. In GIST and LX-2 cells, only the 31-kDa
KITLG band was detected (Figure S1B). We validated our
method in Sl/Sl4 fibroblasts lacking full-length Kitl and in Sl/Sl4
cells engineered to stably express Kitl248 (Figure S1C) or Kitl220
(not shown) [3]. KITLG expression was similar in KIT+ GIST-T1
cells expressing WT KIT, in KIT+ GIST882 and KITlow/–
GIST48B cells lacking a WT KIT allele, and in KIT- LX-2 cells
(Figure 1D-E). These results demonstrate Kitl/KITLG
expression in all our models.
Endogenous KITLG stimulates the proliferation of GIST
cells expressing WT KIT
To investigate the role of autocrine/paracrine KITLG–KIT
signaling in GIST proliferation, we examined the effect of
KITLG immunoneutralization and RNAi-mediated knock-down
in GIST cells expressing or lacking WT KIT. Control
experiments verified the induction of KIT phosphorylation on
Y721, the docking site for the p85 subunit of PI3K [1], by
exogenous KITLG in GIST-T1 cells containing a heterozygous
activating KIT mutation (Figure 1A; see reagent concentrations,
exposure times, replicate numbers and other statistical details
in the figures and their legends). KIT phosphorylation was also
increased, albeit to a lesser degree, in GIST-T1-5R cells,
derivatives of GIST-T1 cells containing an additional, imatinib-
resistant KIT mutation. In contrast, no ligand-dependent KIT
phosphorylation was detected in GIST882 cells, which are
homozygous for the activating KITK642E mutation. Culturing with
anti-human KITLG neutralizing antibody [37] for 4 days
inhibited the proliferation of GIST-T1 cells by ~40% (IC50: ~9
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Figure 1.  Contribution of KITLG-activated KIT signaling to baseline proliferation of GIST and LX-2 cells.  A, KIT Y721
phosphorylation was activated by exogenous rhKITLG (100 ng/mL for 10 min following 2 h serum deprivation [13,35]) in GIST-T1
cells containing a heterozygous activating KIT mutation (n=4/group) and in GIST-T1-5R cells containing an additional, imatinib-
resistant KIT mutation (n=6/group), but not in GIST882 cells lacking a WT KIT allele (n=5/group). B, Culturing with anti-human
KITLG neutralizing antibody for 4 days inhibited baseline proliferation of GIST-T1 cells (P<0.001; n=3; regression and 95%
confidence band are shown as solid and dashed lines, respectively) and GIST-T1-5R cells (P<0.001; n=6). The effect of KITLG
immunoneutralization on GIST-T1 cells was blocked by preabsorbing the antibody with 10-fold molar excess of rhKITLG (see open
symbols in the left panel, second row; n=3/group). KITLG immunoneutralization did not inhibit the proliferation of GIST882 or
GIST48B cells lacking a WT KIT allele (note that GIST48B cells also express very low to undetectable levels of KIT protein, see
Figure S1E) and of LX-2 cells lacking KIT protein (Figure S1E) (n=3/cell line). C, Inhibition of the proliferation of GIST-T1 and GIST-
T1-5R cells by siRNA-mediated knock-down of KITLG (n=4/cell line/group; PGIST-T1: day 2: 0.008, days 4, 6 and 8: <0.001; PGIST-T1-5R:
day 2: <0.02, day 4: 0.004, days 6 and 8: <0.001).
doi: 10.1371/journal.pone.0076822.g001
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ng/mL) and GIST-T1-5R cells by ~34% (IC50: ~26 ng/mL)
(Figure 1B), whereas the same treatment had no effect on KIT+
GIST882 and KITlow/– GIST48B cells lacking WT KIT allele or on
KIT- LX-2 cells. The effect of KITLG immunoneutralization on
GIST-T1 cells was prevented by preabsorbing the antibody
with 10-fold molar excess of rhKITLG (Figure 1B). The
proliferation of both GIST-T1 and GIST-T1-5R cells could also
be inhibited by RNAi targeting KITLG (Figure 1C). These
findings provide direct evidence that activation of KIT signaling
by endogenous KITLG contributes to the proliferation of GIST
cells expressing WT receptors.
IGF1 stimulates Kitl protein expression
To investigate the direct effects of IGF1 on Kitl expression,
we first administered 150 µg/kg LR3-rhIGF1, a potent IGF1
analog with reduced affinity for IGF-binding proteins, to 14-16-
day-old BALB/c mice in a single i.p. injection and measured Kitl
protein in the gastric tunica muscularis by Western blotting. Kitl
expression increased in a time-dependent manner, with
maximum effect occurring at 24 h (Figure 2A). In short-term
cultures of intact gastric corpus+antrum muscles from 14-16-
day-old BALB/c mice, 100 ng/mL rhIGF1 caused maximum
stimulation of Kitl protein between 12 and 24 h (Figure 2B).
This effect was dose-dependent, plateauing between 100 and
300 ng/mL (Figure 2C). The upregulation of Kitl expression
seen in response to 100 ng/mL rhIGF1 applied for 18 h was
also verified using Actb as loading control (Figure S2).
Tyrphostin AG1024, a specific inhibitor of IGF1R and insulin
RTK activity [30], reduced the rhIGF1 effect on Kitl (Figure 2D)
indicating that it was likely mediated by IGF1R or insulin
receptor/IGF1R heterodimers [15].
Multiple signaling pathways mediate IGF1-induced Kitl
protein expression
To investigate the mechanisms of IGF1-induced Kitl
expression, we first detected the phosphorylation of key IGF1
signaling intermediates [19,20] in murine gastric muscles
stimulated by exogenous IGF1 (Figure 2E-F). rhIGF1 elicited
time-dependent increase in the phosphorylation of AKT,
GSK3β, p70S6K and ERK1/2: After 1 h, we detected increased
activating phosphorylation on S473/S474/S472 of AKT
isoforms, p70S6K phosphorylation on T389 [19], elevated
ERK1 and ERK2 phosphorylation on T202/Y204 and T185/
Y187, respectively, and increased inhibitory phosphorylation on
S9 of GSK3β [45] (Figure 2E). After 3 h, ERK1/2
phosphorylation returned to baseline but phosphorylated AKT,
p70S6K and GSK3β remained elevated (Figure 2F). We then
probed the contribution of these intermediates to IGF1-induced
Kitl expression by using pathway-specific inhibitors (Figure
2G): rhIGF1-stimulated Kitl expression was reduced by AKT
Inhibitor X [31]; by rapamycin, which selectively inhibits the
activation of p70S6K by MTOR complex 1 [19]; and by
PD98059, a selective MEK inhibitor [32]. SB415286, a
selective competitive inhibitor of ATP binding to GSK3α/β and
functional mimic of AKT-mediated GSK-3 phosphorylation and
inactivation [27], only minimally increased Kitl expression
beyond the near-maximal stimulation caused by IGF1. These
results indicate cooperation among several major IGF1
intermediate pathways in stimulation of Kitl expression.
GSK-3 inhibition (GSK3i) stimulates Kitl expression
without directly activating pathways involved in cell
growth and proliferation
To better understand the role of GSK3i in the stimulation of
Kitl expression, we evaluated the effects of SB415286 in the
absence of exogenous IGF1 in isolated murine gastric
muscles. Under this condition, SB415286 stimulated Kitl
expression (Figure 3A). Despite mimicking the effect of IGF1
on Kitl, SB415286 did not stimulate the expression of cyclin D1,
a key mediator of IGF1-induced cell cycle progression [15]
(Figure 3B), or the phosphorylation of p70S6K and ERK1/2
(Figure 3C) at time points when IGF1 effects on these
parameters were prominent. We obtained similar results with
SB216763, another ATP-competitive GSK3α/β inhibitor and
TDZD-8, a non-ATP-competitive GSK3α/β inhibitor (Figures S3
and S4). Thus, GSK3i alone specifically stimulates Kitl
expression offering a pharmacological approach to increase
Kitl/KITLG levels in gastrointestinal muscles without
reproducing IGF1’s actions promoting cellular stress, aging and
cancer [14,15].
IGF1 and GSK3i activate Kitl/KITLG transcription
Next, we investigated the role of gene transcription in the
IGF1 and GSK3i effects. In primary human smooth muscle
cells (Figure 4A), KITLG mRNA was expressed in a serum-
dependent fashion (Figure 4B). In intact murine smooth
muscles, 12-h exposure to rhIGF1 or SB415286 upregulated
Kitl mRNA (Figure 4C). In primary murine smooth muscle cells,
SB415286 stimulated endogenous Kitl expression (Figure 4D)
and activated transcription from an episomally expressed
human KITLG promoter- luciferase construct (Figure 4E). In
LX-2 and GIST-T1 cells, both rhIGF1 and SB415286 increased
KITLG mRNA (Figure 4F, H), although SB415286 was more
effective in LX-2 cells and IGF1 had a greater effect in GIST-T1
cells. KITLG promoter activity was also increased by both IGF1
and SB415286 (Figure 4G, I). In both cell lines, IGF1 displayed
more rapid action on KITLG promoter activity than SB415286.
Nevertheless, these results indicate that the stimulation of Kitl
protein expression by IGF1 and GSK3i primarily occurs at the
transcriptional level and led us to investigate the nature of
chromatin remodeling events that account for this effect.
Coordinated chromatin modifications underlie the
activation of Kitl/KITLG transcription by IGF1 and
GSK3i
We performed ChIP-PCR targeting the core Kitl promoter in
murine gastric smooth muscles exposed for 6 h to rhIGF1 or
SB415286 using antibodies against several activating and
repressive histone marks and the polycomb group (PcG)
HKMT EZH2. Control experiments using “non-immune” mouse
IgG and antibodies against the functionally irrelevant Gapdh
protein revealed little recovery of Kitl promoter DNA and no
variation among treatments (Figure S5). The biological role of
the enzymes and other proteins involved in the establishment
of the targeted modifications was then validated with the aid of
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Figure 2.  Kitl protein expression is stimulated by IGF1 via multiple IGF1R-activated pathways.  A, Time-dependent
stimulation of Kitl expression in the gastric tunica muscularis of 14-16-day-old BALB/c mice by the potent IGF1 analog LR3-rhIGF1
administered in a single 150 µg/kg dose i.p.; n=5 mice/group. B, Time-dependent stimulation of Kitl expression by 100 ng/mL
rhIGF1 in gastric corpus+antrum tunica muscularis organotypic cultures from 14-16-day-old BALB/c mice; n=4-5/group. C,
Concentration-dependent stimulation of Kitl protein expression by 18-h rhIGF1 treatment; n=7 organotypic cultures/group. D,
Blockade of the rhIGF1-induced Kitl expression in organotypic cultures by AG1024 (1 µM), a specific inhibitor of IGF1/insulin
receptor tyrosine kinase activity; n=4/group. E-F, Effects of 1-h (E) and 3-h (F) rhIGF1treatment on AKT (S473/S474/S472), GSK3β
(S9), p70S6K (T389) and ERK1/2 (T202/Y204 and T185/Y187) phosphorylation; n=5 organotypic cultures/group. G, Blockade of
rhIGF1-induced Kitl expression in organotypic cultures by specific inhibitors of AKT (AKT Inhibitor X; 150 µM), MTOR–p70S6K
(rapamycin; 1.5 nM) and MEK–ERK (PD98059; 50 µM); n=5-16/group. The GSK-3 inhibitor SB415286 (30 µM), which is expected
to mimic, rather than inhibit, the effect of the IGF1-induced inhibitory phosphorylation of GSK-3, had no significant effect. Kitl and
Gapdh or total (T) and phosphorylated proteins (P) were simultaneously detected in the same samples by two-color
immunofluorescence (Figure S1). Representative immunoblots show identical areas of the blots imaged at different wavelengths.
Box plots show medians and interquartile ranges; bar graphs indicate means±SEM. Data were normalized to the control groups
indicated in the panels (dashed lines). Groups marked by asterisk are different from the control group, and groups not sharing the
same superscript letter are different from each other (P<0.05 by post-hoc multiple comparisons). IGF1 stimulated Kitl expression in
gastric smooth muscles in vivo and in vitro in a time- and concentration-dependent manner by activating IGFR1 and the AKT–
GSK3, MTOR–p70S6K and ERK MAPK pathways.
doi: 10.1371/journal.pone.0076822.g002
Membrane-to-Nucleus Signaling Links IGF1R and KIT
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e76822
pharmacological inhibitors and RNAi in LX-2 and GIST-T1 cells
using KITLG expression as readout. We first studied the role of
histone acetylation, which is almost invariably associated with
transcriptional activation [46] (Figure 5). In murine gastric
smooth muscles, both rhIGF-I and SB415286 increased the
occupancy of the Kitl promoter by H4ac (which may include
acetylated K5, K8, K12 and K18 [47]) (Figure 5A), whereas
increased occupancy by H3K9ac was only detected in
response to GSK3i (Figure 5B). Consistent with these findings,
inhibition of HDAC classes I-II with SAHA led to a dose-
dependent increase in KITLG mRNA in LX-2 cells (Figure 5C).
The role of increased H3K9 acetylation in the GSK3i effect was
supported by the dose-dependent reduction of SB415286-
induced increase in KITLG mRNA by the p300/PCAF HAT
inhibitor garcinol (Figure 5D). In GIST-T1 cells, the
transcriptional effects of HDAC inhibition could not be
determined due to rapid cell death likely reflecting the apoptotic
effects of acetylation and consequent loss of function of the KIT
chaperone heat shock protein 90 [48].
Next, we examined whether histone methylation, a
biochemical mechanism associated with long-term
transcriptional memory, also contributes to the regulation of
Kitl/KITLG expression. First we studied the activating
H3K4me2 mark, which binds enhancer and promoter regions
and gene bodies of actively transcribed or transcriptionally
poised but repressed, tissue-specific genes [49]. Whereas
rhIGF1 increased the level of H3K4me2 on the Kitl promoter
~2.8-fold, SB415286 only had a modest effect (Figure 6A).
Since transcriptional activation mediated by H3K4 methylation
is often antagonized by PcG complexes [50,51], we also
measured the association with the Kitl promoter of the PcG
HKMT EZH2 and the repressive H3K27me3 modification it
catalyzes [50]. These experiments showed that rhIGF1 and
SB415286 reduced the presence of both EZH2 and the
H3K27me3 mark on the Kitl promoter (Figure 6B-C). To
mechanistically explore the functional impact of the PcG-
mediated repression on Kitl/KITLG expression, we inhibited
EZH2 activity with the indirect HKMT inhibitor Adox [29]. Adox
increased KITLG mRNA in GIST-T1 cells ~2.9-fold (Figure 6F)
but had more modest, albeit statistically significant, effects in
murine gastric smooth muscles and LX-2 cells (Figure 6D-E).
Figure 3.  GSK3i stimulates Kitl expression without activating cyclin D1 expression and p70S6K and ERK1/2
phosphorylation.  The GSK3α/β inhibitor SB415286 was applied to organotypic cultures of gastric corpus+antrum muscles from of
14-16-day-old BALB/c mice at 30 µM. A, Effect of 18-h application of SB415286 on Kitl expression; n=5/group. B, Effect of the same
treatment on cyclin D1 expression; n=3/group. C, Effects of 1-h exposure to SB415286 on p70S6K and ERK1/2 phosphorylation;
n=3/group. See Figure 2 for further details.
doi: 10.1371/journal.pone.0076822.g003
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Figure 4.  IGF1 and GSK3i stimulate Kitl/KITLG transcription.  Results obtained in murine and human smooth muscle cells (A-
E), human LX-2 stellate cells (F-G) and human GIST-T1 cells (H-I) are shown. A, Hoffman modulation contrast image of primary
human gastric smooth muscle cells. B, KITLG mRNA (total: soluble+membrane-bound) was readily detectable in primary human
smooth muscle cells (passage 3) maintained with Smooth Muscle Growth Medium-2 containing insulin, hFGF-B, hEGF and 5% FBS
(Lonza) but not in 24-h growth factor- and serum-deficient basal medium. C, Both IGF1 (100 ng/mL) and the GSK3α/β inhibitor
SB415286 (30 µM) stimulated Kitl expression in murine gastric tunica muscularis organotypic cultures (n=3/group). D-E, SB415286
stimulated endogenous Kitl expression in murine primary gastric smooth muscle cells (D; n=3/group) and KITLG transcriptional
activity in the same cell type transfected with a KITLG promoter (-2120 bp to +407 bp)-pGL3 luciferase construct (E; n=3/group).
IGF1 (100 ng/mL; n=3/group) and SB415286 (30 µM; n=6/group) also increased endogenous KITLG mRNA expression in LX-2 (F)
and GIST-T1 cells (H) and stimulated KITLG promoter activity in a time-dependent fashion (LX-2: n=6-9/group; G; GIST-T1: n=3-11/
group; I). Groups marked by asterisk are different from the control group, and groups not sharing the same superscript letter are
different from each other (P<0.05 by post-hoc multiple comparisons).
doi: 10.1371/journal.pone.0076822.g004
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These results indicate that PcG inhibits Kitl/KITLG expression
under basal conditions.
We also studied the involvement H3K9 methylation in the
regulation of Kitl/KITLG transcription. The best understood
function of H3K9me2/3 is stable gene silencing through
heterochromatin formation [52]. This process requires the
binding of HP1 proteins and consequent recruitment of the
H3K9me1/2 HKMTs G9A and GLP and the H3K9me3 HKMT
SUV39H1, which reinforce the silencing of genes located within
the constitutive heterochomatin and initiate the repression of
genes previously embedded in euchromatin [53]. In murine
gastric muscles, we detected both H3K9me2 and H3K9me3 on
the Kitl promoter (Figure 7A-B), and both marks were reduced
by rhIGF1. GSK3i had less pronounced effects. In LX-2 cells,
KITLG mRNA increased in response to RNAi targeting HP1γ
(CBX3) but was unaffected by HP1α (CBX5) or HP1β (CBX1)
knockdown (Figure 7C-D). These findings are consistent with
HP1γ’s role in euchromatic silencing [53]. In response to the
G9A/GLP inhibitor BIX-01294 we also detected a dose-
dependent increase in KITLG mRNA in LX-2 cells, and a ~100-
fold increase in GIST-T1 cells (Figure 7E-F). In LX-2 cells,
KITLG expression was also dose-dependently stimulated by
chaetocin, a specific inhibitor of SUV39H1 (Figure 7G). The
transcriptional effects of chaetocin could not be assessed in
GIST-T1 cells due severe cytotoxicity. These results reveal an
important role for HP1γ and H3K9me2/3 in IGF1-mediated Kitl/
KITLG expression.
In summary, our data support the model that IGF1 promotes
autocrine/paracrine Kitl/KITLG–KIT signaling in part via AKT-
mediated GSK3i and coordinated chromatin modifications
favoring increased Kitl/KITLG transcription, and that these
effects can be uncoupled from the direct mitogenic actions of
IGF1. To allow Kitl/KITLG expression, IGF target cells must
increase the levels of activating H4ac, H3K9ac and H3K4me2
marks and decrease the levels of the repressive marks
H3K27me3 and H3K9me2/3. While IGF1 and GSK3i appeared
to exert their effects via the same general mechanisms, they
also showed differences in their actions. The results presented
herein outline a novel RTK cross-talk that regulates ligand-
induced KIT activation in both physiologic/developmental and
oncogenic contexts.
Discussion
Adequate stimulation of the KIT receptor by its ligand Kitl/
KITLG is required for diverse developmental and physiological
processes such as hematopoiesis, pigmentation,
gametogenesis, spatial learning, cardiomyocyte differentiation
and repair, vasculogenesis and angiogenesis, lung function
and gastrointestinal motility [1,2]. In contrast, ligand-
independent activation of KIT due to oncogenic mutations is
associated with several types of cancer such as GIST,
seminomas, acute myeloid leukemia, melanomas and systemic
mastocytosis [1,6]. However, abnormal ligand-dependent
signaling occurring in the absence of mutations and reflecting
altered expression of KIT and/or Kitl/KITLG contributes to the
pathogenesis of not only non-neoplastic disorders such as
gastrointestinal dysmotilities and allergies [1,21,22] but also
various cancers including subsets of GIST, acute myeloid
leukemia, small-cell lung carcinoma, breast and colorectal
cancer, ovarian cancer and neuroblastoma [1,9,11-13].
Therefore, understanding the factors and mechanisms
regulating Kitl/KITLG expression will likely provide novel
therapeutic tools for both functional disorders and cancers. We
Figure 5.  Role of histone acetylation in the activation of Kitl/KITLG transcription by IGF1 and GSK3i.  A, Increased
occupancy of the Kitl core promoter region by H4ac in response to 6-h rhIGF1 (100 ng/mL) and SB415286 (30 µM) treatment in
murine gastric smooth muscles. Only SB415286 increased occupancy by H3K9ac (B). Representatives of two independent
experiments, each performed in triplicates, are shown. C, Dose-dependent stimulation of KITLG expression in LX-2 cells by 24-h
treatment with the class I-II HDAC inhibitor SAHA (n=3/group). D, Dose-dependent inhibition of the SB415286-induced stimulation
of KITLG expression by the p300/PCAF HAT inhibitor garcinol (24 h) in LX-2 cells (n=3/group). Drugs were applied following 24-h
serum deprivation. Groups marked by asterisk are different from the control group, and groups not sharing the same superscript
letter are different from each other (P<0.05 by post-hoc multiple comparisons).
doi: 10.1371/journal.pone.0076822.g005
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have previously shown that long-term IGF1 treatment of intact
murine gastric tunica muscularis increases Kitl availability in
part by stimulating the growth and survival of smooth muscle
cells, the primary source of Kitl in this tissue [22]. Here we
demonstrate that IGF1 directly stimulates Kitl/KITLG
expression in gastrointestinal smooth muscles, the natural
microenvironment for ICC and GIST [8,21,22], in GIST cells
and in LX-2 cells derived from hepatic stellate cells [33], the
presumed niche for KIT+ hepatic progenitors [54], inflammatory
cells [55] and hepatocellular carcinoma [25].
Our study outlines a transcriptionally mediated autocrine/
paracrine loop between two distinct RTK signaling systems, the
Kitl/KITLG–KIT and IGF–IGF1R systems. Locally produced and
circulating IGF1 affects almost all tissues and plays key roles in
the regulation of body size, skeletal acquisition, muscle mass,
reproduction, metabolism and life/health span [56]. There is
also a strong positive correlation between circulating IGF levels
and cancer risk and prognosis [14,15]. IGF1R signaling
facilitates cell cycle progression mainly at the G1-S transition
reflecting increased cyclin D1 transcription and translation
stimulated via the ERK MAPK and AKT–MTOR–p70S6K
pathways, respectively [15]. As our data show, increased
IGF1R activation (in part from autocrine IGF1; Figure S1G)
can, in turn, increase Kitl/KITLG expression and thus
potentially amplify its oncogenic potential in KIT-expressing
cells and tissues. For example, in WT GIST, an IGF2-IGF1R
autocrine/paracrine loop sustained by overexpression of both
the receptor and its ligand in the same tumor microenvironment
[5,16,17,57,58] may activate a secondary autocrine/paracrine
loop formed by KITLG and WT KIT leading to increased KIT
phosphorylation (refs. 9,10,13 and present results) and cell
proliferation. Indeed, our data in the heterozygous KIT mutant
Figure 6.  Role of trithorax- and polycomb-mediated histone modifications in IGF1- and GSK3i-induced activation of Kitl/
KITLG transcription.  A, Increased occupancy of the Kitl core promoter by the trithorax group-mediated, activating H3K4me2
histone modification in response to 6-h rhIGF1 (100 ng/mL) and SB415286 (30 µM) treatment in murine gastric smooth muscles. B-
C, Reduced occupancy of the Kitl core promoter by the PRC2-mediated, repressive H3K27me3 histone modification (B) and by the
PRC2 histone methyltransferase EZH2 (C) in response to rhIGF1 and SB415286 in the same tissues. D-F, Stimulation of KITLG
expression by the indirect histone methyltransferase inhibitor Adox in murine gastric smooth muscles (D), LX-2 cells (E) and GIST-
T1 cells (F) (n=3/group). Adox was applied for 72 h following 24-h serum deprivation. See further details in the legend to Figure 5.
doi: 10.1371/journal.pone.0076822.g006
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GIST-T1 cells indicate that autocrine/paracrine KITLG-
mediated KIT signaling may account for ~40% of baseline
proliferation even in cells with a secondary, imatinib-resistant
mutation and can be inhibited with antibodies or RNAi targeting
KITLG. Since imatinib preferentially targets mutant receptors
[6,9], inhibiting the IGF–IGF1R and KITLG–KIT coupled
autocrine/paracrine loops may be beneficial in GIST, which are
in most cases heterozygous for a given KIT mutation and
continue expressing WT KIT protein [5]. However, the
contribution of this pathway to GIST growth in vivo remains to
be established. Interestingly, even in GIST lacking WT KIT,
anti-KIT antibodies inhibited tumor growth with an efficacy
similar to what we observed in GIST-T1 cells following KITLG
immunoneutralization, although the former effect was attributed
to increased phagocytosis and stimulation of KIT degradation
rather than prevention of KITLG binding [59]. In hepatic stellate
cells, KITLG expression stimulated by IGF1R signaling may
facilitate the KIT-dependent recruitment of inflammatory cells in
injury and fibrosis [55] and progenitor cells in hepatic failure
[54], and may thus be associated with both disease
progression and tissue regeneration. In gastrointestinal
neuromuscular tissues, stimulation of Kitl/KITLG–KIT signaling
could prevent or counter ICC loss associated with several
motility disorders and conditions including diabetic
gastroparesis [22,60] and aging [43,61], where reduced Kitl/
KITLG expression is a pathogenetic factor [22,43]. Since ICC
differentiation cannot be supported solely by supplying free Kitl/
KITLG [2,21], pharmacological interventions will likely require
stimulation of local production of both soluble and membrane-
associated Kitl/KITLG, which, as our data show, could be
Figure 7.  Role of reduced H3K9 methylation in the activation of Kitl/KITLG transcription by IGF1 and GSK3i.  A-B, Reduced
occupancy of the Kitl core promoter by the repressive H3K9me2 (A) and H3K9me3 (B) histone modifications in response to 6-h
rhIGF1 (100 ng/mL) and SB415286 (30 µM) treatment in murine gastric smooth muscles. C-D, Probing the role of HP1 isoforms in
transcriptional repression of KITLG in LX-2 cells by siRNA- (CBX5: HP1α; 25 nM, 72 h; C) or shRNA-mediated knock-down (CBX1:
HP1β; CBX3: HP1γ; 30 µg plasmid, 72 h; D). Note activation of KITLG expression by shRNA-mediated knock-down of HP1γ (n=3/
group). E-F, Stimulation of KITLG expression by the G9A/GLP H3K9me1/2 HKMT inhibitor BIX-01294 in LX-2 cells (E) and GIST-T1
cells (F) (n=3/group). G, Stimulation of KITLG expression by the H3K9 HKMT inhibitor chaetocin in LX-2 cells (n=3/group). Drugs
were applied for 24 h following 24-h serum deprivation. See further details in the legend to Figure 5.
doi: 10.1371/journal.pone.0076822.g007
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accomplished by IGF1 administration or GSK3i. In summary,
the crosstalk between the IGF and the Kitl/KITLG pathways
revealed by our results is potentially important for
understanding and controlling the mechanisms of cell
proliferation in both neoplastic and functional gastrointestinal
diseases such as GIST, liver disease and gastroparesis.
Therefore, it is also important to discuss the information we
have obtained on the pathway mediating signal transduction
from the IGF1R to the nucleus to regulate Kitl/KITLG
expression.
Our initial studies focused on the intracellular kinases that
transduce signals downstream of IGF1R. In our models, Kitl/
KITLG expression could also be stimulated by inhibiting GSK-3
activity with both ATP-competitive and non-ATP-competitive
inhibitors. These results were unexpected because IGF1
effects on Kitl appeared to involve overlapping actions of
several major pathways including the ERK MAPK, AKT and
MTOR–p70S6K pathways, whereas GSK3i stimulated Kitl
expression without increasing ERK1/2 or p70S6K
phosphorylation and cyclin D1 expression at time points when
IGF1 effects on these parameters were prominent. The
potential translational significance of these findings is that
GSK3i may allow the stimulation of KITLG expression e.g. in
patients with ICC loss without concomitant activation of the
pathways that mediate IGF1’s actions promoting cellular stress,
aging and cancer [14,15]. While GSK3i may affect ERK1/2 and
MTOR–p70S6K at other time points, our results agree with
Kuemmerle’s finding that in gastrointestinal smooth muscle
cells, the AKT–GSK3i-mediated and p70S6K- and ERK1/2-
dependent mechanisms are functionally segregated, with AKT-
dependent signaling being involved only in anti-apoptotic but
not in the proliferation-stimulating actions of IGF1 [19,20].
Indeed, despite mediating the β-catenin-stabilizing effect of
WNT signaling, long-term GSK3i has been associated with
reduced, rather than increased, cancer risk possibly due to the
concomitant activation of forkhead transcription factors [28],
and numerous GSK-3 inhibitors are under investigation for their
beneficial effects in diabetes, inflammation, central nervous
system injuries, bipolar disorder, Alzheimer’s disease and
cancer [45].
Subsequently, we investigated how the IGF1- and GSK3i-
induced signaling activates nuclear events to bring about
increased Kitl/KITLG expression. By measuring Kitl/KITLG
transcript levels and KITLG promoter activity we found that Kitl/
KITLG protein expression induced by IGF1 or GSK3i indeed
reflected increased gene transcription. However, our data also
revealed differences in the time-courses of the IGF1 and
GSK3i effects along with preferential stimulation by IGF1 and
GSK3i in GIST-T1 and LX-2 cells, respectively. Therefore, we
studied the role of several repressive and activating histone
modifications, as well as the enzymes and regulatory factors
responsible for their establishment by ChIP and pharmacologic
and RNAi-mediated interventions. In selecting our ChIP targets
we considered that both the mouse and human Kitl/KITLG
promoter contain a CpG island but are unlikely to be DNA-
methylated, given that we detected significant RNA polymerase
II occupancy, baseline expression and transcriptional activity in
our models. We found that activation of Kitl expression in
murine gastric smooth muscles by both IGF1 and GSK3i
elicited coordinated changes in the chromatin involving
reduced and increased occupancy of the Kitl promoter by
repressive and activating histone marks, respectively. These
events involved the activating histone marks H4ac, H3K9ac,
H3K4me2, the repressive marks H3K9me2/3 and H3K27me3,
as well as related enzymes and regulators such as EZH2, G9A,
GLP, SUV39H1, PCAF, HDACs and HP1γ. Our data also
indicated some differences between IGF1 and GSK3i-induced
changes such as preference for H3K4me2- and H3K9ac-
mediated activation by IGF1 and GSK3i, respectively. The
complexity of this system raises the question how these
changes are orchestrated. There is strong evidence that the
process of transcription itself regulates chromatin states [52],
and sequence-specific transcription factors, besides transiently
modulating transcription, contribute to the recruitment of
chromatin modifiers [62]. For example, transcription factors
activated in response to IGF1 signaling or GSK3i may bind to
the promoter and initiate the recruitment and eviction of the
chromatin modifying complexes that establish the activating
and repressive marks, respectively [63]. IGF1 may activate
transcription via ERK and p70S6K signaling [15], by promoting
IGF1R β subunit nuclear translocation and association with
lymphoid enhancer-binding factor 1 [23] and via GSK3i.
Physiological or pharmacological GSK3i can in turn lead to the
loss of inhibitory phosphorylation of several transcription
factors in a stimulus-, promoter- and cellular context-dependent
manner [45]. Indeed, some of these GSK-3-inhibited
transcription factors have putative or verified binding sites in
the promoter region of the KITLG gene [1]. Identification of the
key transcription factors mediating the observed IGF1 and
GSK3i effects on Kitl/KITLG expression is a requisite next step
toward understanding the transcriptional mechanisms that
couple IGF1-IGF1R and Kitl/KITLG–KIT RTK signaling in
physiologic and oncogenic contexts.
Supporting Information
Figure S1.  Kitl/KITLG and IGF1R protein expression and
IGF1 secretion in murine gastric smooth muscles, human
LX-2 stellate cells and GIST cells. A, Detection of Kitl in the
lysate of gastric corpus+antrum muscles from a juvenile
BALB/c mouse. The membrane was simultaneously probed
with antibodies against Kitl and Gapdh (loading control) and
appropriate fluorescent secondary antibodies. Note primary Kitl
band at ~31 kDa and a weaker band at ~43 kDa. The 21-kDa
Kitl band was only borderline detectable. B, In human GIST cell
lines, only the 31-kDa KITLG band was detected. B, Validation
of the Western immunoblotting method. The 31-kDa Kitl band
was also detected in lysates of Sl/Sl4 hematopoietic stromal
cells expressing mKitl248. No Kitl bands were detected in Sl/Sl4
stromal cells lacking full-length Kitl. D, Expression of KITLG
protein in LX-2 human hepatic stellate cells and three human
GIST cell lines. E, Expression of KIT protein in the same cell
lines. The level reported for LX-2 cells represents background
fluorescence as no specific band was detected. Note lack of
correlation between KITLG and KIT expression. F, IGF1R α
and β chain expression in GIST48B cells. G, IGF1 secretion
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into culture media by GIST-T1, GIST882, GIST48B and LX-2
cells. 3000 cells/well were plated into 96-well plates and
cultured in the presence or absence of FBS (GIST-T1,
GIST882, LX-2: 10%; GIST48B: 15%) for 48 h. IGF1 was
measured in the harvested cell-free media using the Quantikine
Human IGF1 Immunoassay kit (DG100, R&D systems). Note
differential responses to FBS.
(TIF)
Figure S2.  Kitl protein expression is stimulated by IGF1.
Stimulation of Kitl expression, detected using Actb as
reference, by 18-h treatment with 100 ng/mL rhIGF1 in gastric
corpus+antrum tunica muscularis organotypic cultures from
14-16-day-old BALB/c mice (n=3/group). Kitl and Actb were
simultaneously detected in the same samples by two-color
immunofluorescence. Representative immunoblots show
identical areas of the blots imaged at different wavelengths.
The degree of Kitl upregulation was statistically
indistinguishable from the increase detected using Gapdh as
loading control (1.89±0.21-fold vs. 2.07±0.15-fold, P=0.583).
(TIF)
Figure S3.  SB216763 stimulates Kitl expression without
activating cyclin D1 expression and p70S6K and ERK1/2
phosphorylation. GSK3α/β inhibitor SB216763 was applied to
organotypic cultures of gastric corpus+antrum muscles from of
14-16-day-old BALB/c mice at 3 µM. A, Effect of 18-h
application of SB216763 on Kitl expression; n=5/group. B,
Effect of the same treatment on cyclin D1 expression; n=3/
group. C, Effects of 1-h exposure to SB216763 on p70S6K and
ERK1/2 phosphorylation; n=3/group. See Figure 2 for further
details.
(TIF)
Figure S4.  TDZD-8 stimulates Kitl expression without
activating cyclin D1 expression and p70S6K and ERK1/2
phosphorylation. The non-ATP-competitive GSK3α/β inhibitor
TDZD-8 was applied to organotypic cultures of gastric corpus
+antrum muscles from of 14-16-day-old BALB/c mice at 10 µM.
A, Effect of 18-h application of TDZD-8 on Kitl expression; n=6/
group. B, Effect of the same treatment on cyclin D1 expression;
n=3/group. C, Effects of 1-h exposure to SB216763 on p70S6K
and ERK1/2 phosphorylation; n=3/group. See Figure 2 for
further details.
(TIF)
Figure S5.  Negative controls for the ChIP experiments. A,
Low recovery of Kitl promoter DNA by ChIP performed in
murine gastric smooth muscles with non-immune mouse IgG
(mIgG) or anti-Gapdh antibody relative to input chromatin or
ChIP with anti-RNA polymerase II (RNA pol II) antibody. B-C,
Unchanged recovery of Kitl promoter sequence in response to
6-h rhIGF1 (100 ng/mL) and SB415286 (30 µM) treatment in
murine gastric smooth muscles following ChIP using mIgG (B)
or anti-Gapdh antibody (C). Representatives of two
independent ChIP experiments, each performed in triplicates,
are shown.
(TIF)
Table S1.  Antibodies used in Western immunoblotting
studies.
(PDF)
Table S2.  Antibodies used in chromatin
immunoprecipitation (ChIP) studies.
(PDF)
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